A Member of the Cancer Information Network
Cancer Information by State:
  arrow Patient Home   arrow Professional Home   arrow Newsletters   arrow Feedback Survey  
Main Menu
Quick Links
Information by Disease
Cancer News
Conference Coverage
Oncology Stocks
AZN$44.82-0.37 (-0.82%)
NVS$53.13-0.16 (-0.3%)
SNY$37.67-0.01 (-0.03%)
GSK$41.530.06 (0.14%)
click here
Conference Coverage
American Society of Hematology 2006 - Summary Coverage
Date: December 9-12, 2006
Location: Orlando, Florida

The content presented here was prepared by independent authors under the editorial supervision of OncoEd and is not endorsed or sanctioned by the American Society of Hematology.
American Society of Hematology 2006 Conference Summaries
Date:
Location:
Author:
Advances in the Treatment of High-Grade Non-Hodgkin's Lymphoma: Report from the 2006 American Society of Hematology Meeting

Advances in Drug Treatment of Chronic Myeloid Leukemia (CML): Report from the 2006 American Society of Hematology Meeting

Advances in the Treatment of Low-Grade Non-Hodgkin's Lymphoma (NHL): Report from the 2006 American Society of Hematology Meeting

Advances in the Treatment of Myelodysplastic Syndrome: Report from the 2006 American Society of Hematology Meeting


Advances in the Treatment of Immune Thrombocytopenic Purpura: Report from the 2006 American Society of Hematology Meeting

Developments in Supportive Care: An Update from the 2006 American Society of Hematology Meeting


Developments in the Treatment of Acute Lymphoblastic Leukemia: Updates from the 2006 American Society of Hematology Meeting


Radio-Immunotherapy with Zevalin®: Updates from the 2006 American Society of Hematology Meeting
 

An Update of Treatments for Multiple Myeloma: Results from the 2006 American Society of Hematology Meeting

American Society of Hematology 2006 News Stories
Active Immunotherapy with FavId® and Leukine® May Be Effective after Rituxan® Treatment for Follicular Lymphoma (1/25/2007)

Sprycel® Superior to High-Dose Gleevec for Gleevec-Resistant CML (1/18/2007)

Sprycel® Effective in Gleevec® Resistant or Intolerant Patients with CML in Chronic Phase (1/16/2007)

Mylotarg® May Decrease Relapse Rate in Patients with Newly Diagnosed AML (1/16/2007)

High-Dose Sequential Chemotherapy with Rituxan® is Superior to CHOP-R for Poor Risk Follicular Lymphoma (1/11/2007)

2007 Conferences



© 1998-2007 CancerConsultants.com  All Rights Reserved.